Manufacturer Requested Reimbursement Criteria1:
Eli Lilly Canada Inc. is requesting reimbursement of tirzepatide, consistent with a subset of the target Health Canada indication, for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.
For the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. • 1 to 3 oral antihyperglycemic agents (any one or combination of metformin, sulfonylurea, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), when diet and exercise plus the baseline treatment does not achieve adequate glycemic control. • basal insulin with or without metformin, when diet and exercise plus basal insulin with or without metformin do not achie...
|Call for patient/clinician input open||14-Jul-22|
|Call for patient/clinician input closed||02-Sep-22|
- Patient input submission received from Diabetes Canada
- Submission was not accepted for review on 26 Aug 2022
Last Updated : September 6, 2022